{"id":"f3f9f7a4-d2c3-55b2-90ad-44b1fa545de6","stable_key":"0ad8610d-d575-5870-b7cd-763a9f750783:copper-wilson-trientine-maintenance","predicate":"noninferior_for","statement":"Trientine tetrahydrochloride was noninferior to penicillamine for the specified non-ceruloplasmin copper endpoint at 24 weeks in stable adults with Wilson disease.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"7f6771bd-0532-5270-9e93-91c4eeea0d8e","mechanism_event_label":"A copper-binding treatment maintained control in this defined patient group.","subject":{"id":"d539fdba-c7f3-5401-a8dd-94202342d102","slug":"trientine-tetrahydrochloride","display_name":"Trientine tetrahydrochloride","entity_type_key":"small_molecule"},"object":{"id":"69d377a4-a080-5ee8-88b5-9d9a1dc177a7","slug":"wilson-maintenance-copper-control","display_name":"Copper control during maintenance treatment of Wilson disease","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"7f6771bd-0532-5270-9e93-91c4eeea0d8e","stable_key":"0ad8610d-d575-5870-b7cd-763a9f750783:copper-wilson-trientine-maintenance-event","event_type":"observed_intervention","label":"A copper-binding treatment maintained control in this defined patient group.","description":"Trientine tetrahydrochloride was noninferior to penicillamine for the specified non-ceruloplasmin copper endpoint at 24 weeks in stable adults with Wilson disease.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"bd86bed3-74e0-56fd-b36a-d289edda2e9e","slug":"penicillamine","display_name":"Penicillamine","entity_type_key":"small_molecule"},"role":"active comparator","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"05dae672-bbd9-585d-8713-ccfe9e14d26a","slug":"atp7b","display_name":"Human copper-transporting ATPase ATP7B","entity_type_key":"protein"},"role":"disease-associated transporter","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"d539fdba-c7f3-5401-a8dd-94202342d102","slug":"trientine-tetrahydrochloride","display_name":"Trientine tetrahydrochloride","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"69d377a4-a080-5ee8-88b5-9d9a1dc177a7","slug":"wilson-maintenance-copper-control","display_name":"Copper control during maintenance treatment of Wilson disease","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/copper-research/36183738.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6235ee4003a7016b645aca9e0df7ea34076b266ebecb33bb878ce75e2c052166\", \"start_char\": 0, \"end_char\": 4337, \"text_sha256\": \"6235ee4003a7016b645aca9e0df7ea34076b266ebecb33bb878ce75e2c052166\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Randomized open-label CHELATE maintenance noninferiority trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Fifty-three adults previously stable on penicillamine for at least a year; trientine tetrahydrochloride versus penicillamine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Maintenance trial in stable adults, not initial treatment of severe disease. Noninferiority is not superiority and does not validate general detoxification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Copper research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"copper","display_name":"Copper","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Human adults with stable Wilson disease","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A copper-binding treatment maintained control in this defined patient group.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[copper-p36183738] Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. (2022). https://pubmed.ncbi.nlm.nih.gov/36183738/ DOI: 10.1016/s2468-1253(22)00270-9","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Circulating non-ceruloplasmin copper and clinical stability","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"8641be5e-ec7e-5be4-bdab-7a3a4fd7b665","evidence_kind":"source_excerpt","locator":"Lines 1469-1480","start_line":1469,"end_line":1480,"excerpt":"### copper-wilson-trientine-maintenance\nTrientine tetrahydrochloride was noninferior to penicillamine for the specified non-ceruloplasmin copper endpoint at 24 weeks in stable adults with Wilson disease.\nCondition category: machinery_impairment\nnutrient_topic: Copper research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A copper-binding treatment maintained control in this defined patient group.\norganism: Human adults with stable Wilson disease\ntissue_or_cell_type: Circulating non-ceruloplasmin copper and clinical stability\nexperimental_model: Randomized open-label CHELATE maintenance noninferiority trial\nlimitations: Maintenance trial in stable adults, not initial treatment of severe disease. Noninferiority is not superiority and does not validate general detoxification.\nexposure: Fifty-three adults previously stable on penicillamine for at least a year; trientine tetrahydrochloride versus penicillamine\nevidence_span: {\"source_cache\": \"artifacts/copper-research/36183738.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"6235ee4003a7016b645aca9e0df7ea34076b266ebecb33bb878ce75e2c052166\", \"start_char\": 0, \"end_char\": 4337, \"text_sha256\": \"6235ee4003a7016b645aca9e0df7ea34076b266ebecb33bb878ce75e2c052166\"}\n[copper-p36183738] Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. (2022). https://pubmed.ncbi.nlm.nih.gov/36183738/ DOI: 10.1016/s2468-1253(22)00270-9","model_system":"Randomized open-label CHELATE maintenance noninferiority trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [copper-p36183738] Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. (2022). https://pubmed.ncbi.nlm.nih.gov/36183738/ DOI: 10.1016/s2468-1253(22)00270-9","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9afba495-cbdc-51aa-998e-70a930dba3be","stable_key":"import-0ad8610d-d575-5870-b7cd-763a9f750783","title":"Copper: transport, cuproenzymes, deficiency, excess and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"84b0f62b2dae6835fa26902be87625c003c6c707492d3007e8f9d15420669008","revision_id":"d7e35b8b-3f77-56d9-90b5-5f542c63f321","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}